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Millions of people around the world drink
water with elevated concentrations of arsenic,
a potent human carcinogen. It is well estab-
lished that chronic exposure to As is associ-
ated with skin, lung, and bladder cancers
[International Agency for Research on Cancer
(IARC) 2004; National Research Council
(NRC) 2001] as well as vascular diseases,
hepatotoxicity, diabetes, and chronic cough
(Mazumder et al. 2005; NRC 2001).
Inorganic As (iAs) is metabolized by reduc-
tion of pentavalent iAs to trivalent, followed by
oxidative methylation to monomethylated As
(MMA), further reduction from pentavalent
MMA to trivalent, and at last methylation to
dimethylated As (DMA) (Vahter 2002). Not
all of the As is fully methylated and some As
remains as iAs and MMA, which are elimi-
nated in the urine along with DMA. In vitro
studies have shown that the trivalent forms,
particularly monomethylarsonous acid
(MMAIII), are generally more toxic than the
pentavalent forms (Nesnow et al. 2002; Styblo
et al. 2000; Vega et al. 2001). Thus, the
observed large variability in the distribution of
metabolites in urine among individuals and
population groups might be associated with
differences in tissue distribution and retention
of toxic metabolites (Vahter 2002). This, in
turn, is likely to lead to variation in susceptibil-
ity. A number of studies indicate that increased
percentage of MMA (%MMA) and decreased
percentage of DMA (%DMA) in urine are
associated with an increase in As retention in
the body (Vahter 2002) and an increase of
toxic effects of As (Chen et al. 2003a, 2003b;
Del Razo et al. 1997; Mäki-Paakkanen et al.
1998; Steinmaus et al. 2006; Tseng et al.
2005; Yu et al. 2000). 
Part of the interindividual variation in As
metabolism may be due to environmental
factors, but earlier studies have shown that
hereditary differences are very likely to con-
tribute (Chung et al. 2002; Vahter 2000). So
far, knowledge on these genetic factors and
their mechanisms is very limited. Recent ﬁnd-
ings from small-scale studies indicate that
polymorphisms in glutathione S-transferase
(GST) omega 1 (GSTO1), which encodes an
enzyme that can reduce pentavalent As
species, might be related to enzyme activity
and patterns of methylated As metabolites
(Marnell et al. 2003; Tanaka-Kagawa et al.
2003). A few studies have indicated that two
other GSTs, GST mu 1 (GSTM1) and GST
theta 1 (GSTT1), have minor effects on As
metabolism as well (Chiou et al. 1997; Marcos
et al. 2006). In another study, involving a
Mexican population, arsenic(+III)methyl-
transferase (AS3MT; also labeled CYT19),
which is known to methylate trivalent As, was
found to have three intronic single nucleotide
polymorphisms (SNPs) that were signiﬁcantly
related to DMA/MMA ratios. However, this
association was only valid for children (Meza
et al. 2005). S-Adenosyl-methionine (SAM) is
the methyl donor for methylation of As
(Marafante et al. 1985), and polymorphisms in
genes involved in SAM metabolism (i.e., one-
carbon metabolism), for example, methylene-
tetrahydrofolate reductase (MTHFR) and
5-methyltetrahydrofolate-homocysteine
methyltransferase (MTR), may affect As
metabolism. 
Our aim was to elucidate how variations
in the various As metabolism-related genes
affect the distribution of As metabolites.
Therefore, we genotyped and phenotyped
inhabitants from a city in the northern
Argentinean Andes, where the inhabitants are
exposed to high levels of As and have an
unusual metabolism (Vahter et al. 1995). The
genes of interest were selected by a) searching
for new and previously reported polymor-
phisms in GSTO1 and AS3MT by sequenc-
ing; and b) screening for previously reported
polymorphisms in GSTM1, GSTT1, GSTO1,
MTR, and MTHFR. 
Materials and Methods 
Study areas and populations. Participants in
this study were women living in San Antonio
Environmental Health Perspectives • VOLUME 115 | NUMBER 4 | April 2007 599
Research
Address correspondence to K. Schläwicke Engström,
Division of Occupational and Environmental
Medicine, Lund University Hospital, 22185 Lund,
Sweden. Telephone: +46 (0) 46 173148. Fax: +46
(0) 46 143702. E-mail: karin.engstrom@med.lu.se
We thank U. Strömberg for statistical advice and
A. Cohen for language editing. 
This research was supported by grants from the
Swedish Council for Working Life and Social
Research; the European Union within the Sixth
Framework Programme for Research and
Technological Development (“PHIME” contract
FOOD-CT-2006-016253); The Swedish Research
Council for Environment, Agricultural Sciences and
Spatial Planning; and the Karolinska Institutet.
The authors declare they have no competing
ﬁnancial interests.
Received 18 September 2006; accepted 8 January
2007.
Genetic Polymorphisms Inﬂuencing Arsenic Metabolism: 
Evidence from Argentina
Karin Schläwicke Engström,1 Karin Broberg,1 Gabriela Concha,2 Barbro Nermell,3 Margareta Warholm,4
and Marie Vahter3
1Division of Occupational and Environmental Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden;
2Toxicology Division, National Food Administration, Uppsala, Sweden; 3Section for Metals and Health, and 4Division of Work
Environment Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
The susceptibility to arsenic-induced diseases differs greatly between individuals, possibly due to
interindividual variations in As metabolism that affect retention and distribution of toxic metabo-
lites. To elucidate the role of genetic factors in As metabolism, we studied how polymorphisms in
six genes affected the urinary metabolite pattern in a group of indigenous women (n = 147) in
northern Argentina who were exposed to approximately 200 µg/L As in drinking water. These
women had low urinary percentages of monomethylated As (MMA) and high percentages of
dimethylated As (DMA). MMA has been associated with adverse health effects, and DMA has the
lowest body retention of the metabolites. The genes studied were arsenic(+III)methyltransferase
(AS3MT), glutathione S-transferase omega 1 (GSTO1), 5-methyltetrahydrofolate-homocysteine
methyltransferase (MTR), methylenetetrahydrofolate reductase (MTHFR), and glutathione S-trans-
ferases mu 1 (GSTM1) and theta 1 (GSTT1). We found three intronic polymorphisms in AS3MT
(G12390C, C14215T, and G35991A) associated with a lower percentage of MMA (%MMA) and a
higher percentage of DMA (%DMA) in urine. The variant homozygotes showed approximately
half the %MMA compared with wild-type homozygotes. These polymorphisms were in strong
linkage, with high allelic frequencies (72–76%) compared with other populations. We also saw
minor effects of other polymorphisms in the multivariate regression analysis with effect modiﬁcation
for the deletion genotypes for GSTM1 (affecting %MMA) and GSTT1 (affecting %MMA and
%DMA). For pregnant women, effect modiﬁcation was seen for the folate-metabolizing genes MTR
and MTHFR. In conclusion, these ﬁndings indicate that polymorphisms in AS3MT—and possibly
GSTM1, GSTT1, MTR, and MTHFR—are responsible for a large part of the interindividual varia-
tion in As metabolism and susceptibility. Key words: arsenic, AS3MT, GSTM1, GSTO1, GSTT1,
metabolism, methylation, MTHFR, MTR, polymorphisms. Environ Health Perspect 115:599–605
(2007). doi:10.1289/ehp.9734 available via http://dx.doi.org/ [Online 8 January 2007]de los Cobres (SAC), a village in the northern
Argentinean Andes. Men were excluded from
the study because they often worked in other
geographic locations for extended periods of
time. All individuals in SAC used drinking
water from the same source; the As concentra-
tion of this water was around 200 µg/L (with
little variation over time) because of the As con-
tent of the bedrock (Concha et al. 2006). Urine
and blood samples were collected from a total
of 148 women in 1997, 2004, and 2005. The
metabolite data from 1997, but no genotype
data, were published previously (Concha et al.
1998b). The group studied in 1997 included
pregnant women only. For analysis of associa-
tions between genotype and As metabolism, we
pooled all of the data for women studied in
2004 and 2005 into one group (n = 111).
Metabolite data was missing for one individual.
Because the metabolite pattern changes during
pregnancy (Concha et al. 1998b), all pregnant
women (from 1997, 2004, and 2005) formed a
separate group (n = 37). 
For women sampled in 2004–2005, data
were available on age (mean, 35; range,
15–76 years), weight (mean, 58; range,
40–88 kg), body mass index (BMI; mean, 25;
range, 17–38 kg/m2), and coca usage (49%
were users). For pregnant women, data were
available on age (mean, 25; range, 16–39 years)
and gestational week (GW; mean, 25; range,
10–37 weeks). The subjects were recruited via
the local radio announcements and hospital
registers and were interviewed about history of
residence, residences of parents and grandpar-
ents, parity, and water consumption. The
interviews revealed that individuals from SAC
were mainly of indigenous (Atacameño) origin,
but there was a variation in Hispanic and
indigenous origin. All individuals were geneti-
cally unrelated. 
The Health Ministry of Salta, Argentina,
and the Ethics Committee of the Karolinska
Institutet approved this study. Before sam-
pling, the responsible community health
worker and the interviewer (one of the
authors) informed the women of all details of
the research project, and all study participants
gave written informed consent.
Arsenic analysis. We determined values of
As in water and total concentration of As
metabolites in urine (U-As) using hydride gen-
eration-atomic absorption spectrophotometry
(HG-AAS) (Vahter et al. 1986). Details of
sample collection have been reported previ-
ously (Concha et al. 1998a). The urine samples
were frozen at the hospital in SAC and kept
frozen (–20°C) for up to 5 months (the 2005
samples were frozen less than 1 month) until
analysis. The speciation of As metabolites (iAs,
MMA, and DMA) in urine for assessment of
the metabolite pattern was performed using
ion-exchange chromatography as described by
Vahter et al. (1995). For the samples collected
in 2004 and 2005, the As metabolites were
speciated using HPLC-HG-inductively cou-
pled plasma mass spectroscopy (ICPMS)
(Agilent 1100 series system and Agilent
7500ce; Agilent Technologies, Waldbronn,
Germany) (Lindberg et al. 2006). Quality con-
trol for the HG-AAS method has been
reported previously (Concha 2001; Crecelius
and Yager 1997; Vahter et al. 1995). In 2002,
we participated in two interlaboratory compar-
isons within the European Union Arsenic
Health Risk and Molecular Epidemiology
(ASHRAM) project, organized by W. Goessler
(University of Graz, Graz, Austria), with good
results (Vahter et al. 2006). After the introduc-
tion of the HPLC-HG-ICPMS method, we
performed intralaboratory comparisons using
HG-AAS, HPLC-HG-atomic fluorescence
spectrometry, and HPLC-HG-ICPMS, show-
ing excellent agreement (Lindberg et al. 2007;
Vahter et al. 2006). We used HPLC-HG-
ICPMS to reanalyze nine remaining urine
samples collected in SAC in 1994 (Concha
et al. 1998a). The correlation between these
new results compared with the 10-year-old
results was 0.97 (%MMA, 0.7–8.3%; con-
centration range, 2–37 µg As/L as MMA). To
compensate for variations in dilution of urine,
the As concentrations were adjusted to the
mean specific gravity of 1.019 g/mL, meas-
ured by a hand refractometer. 
Polymorphism detection and analysis.
DNA was isolated from either whole blood by
a modified salting-out method (Miller et al.
1988), or from buccal cells (by buccal swabs)
using a QIAamp DNA Mini Kit (Qiagen,
Hilden, Germany); this extraction was per-
formed at the Swegene DNA Extraction
Facility at Malmö University Hospital
(Malmö, Sweden). 
Initial screening. For GSTO1 [UniGene
Accession no. Hs.190028; National Center for
Biotechnology Information (NCBI) 2006c]
and AS3MT (UniGene, Hs.123461), sequenc-
ing was performed for all exons (apart from
exon 2 of AS3MT) and flanking regions for
37 selected subjects with low %MMA, from
both groups (2004–2005 group and pregnant
group). Polymorphisms with a variant allele
frequency > 20% were thereafter analyzed in
the entire population. For sequence analysis,
we followed the standard protocol of Applied
Biosystems (Protocol no. 4339920A). We per-
formed polymerase chain reaction (PCR)
cycle-sequencing reactions using Big Dye
Terminator, version 3.1, Cycle-Sequencing
Premix (Applied Biosystems); the DyeEx 96
kit (Qiagen, Hilden, Germany) was used for
removal of unincorporated dye terminators.
For the other genes studied, all individuals
were genotyped by different methods. Primers
for GSTO1 were chosen according to Marnell
et al. (2003) with some modiﬁcations, based
on the sequence of accession no. AY817669
(NCBI 2006a). We chose primers for AS3MT
based on the sequence AY817668. SNPs in
GSTO1 and AS3MT refer to positions within
these sequences. All primers, annealing tem-
peratures, PCR and sequencing conditions,
and quality control information are available
upon request. The sequencing products were
separated with an ABI 3730 DNA Analyzer
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Table 1. Genotype and allele frequencies (%) for all individuals from SAC and previously reported genotype
frequencies from other studies.
SNP, SACb Indigenous European/Hispanic
Genotypea [genotype % (allele %)] American ancestry  ancestry 
AS3MT 12390 n = 112 n = 22 n = 24
GG/GC/CC (G/C) 6/43/51 (28/72) NA (58/42)c  NA (80/20)c
AS3MT 14215 n = 145 n = 22 n = 24
CC/CT/TT (C/T) 6/35 /59 (28/72) NA (62/38)c  NA (90/10)c
AS3MT 35991 n = 146 n = 22 n = 24
GG/AG/AA (G/A) 6/36/58 (24/76) NA (50/50)c NA (52/48)c
GSTM1 n = 139 n = 23
GSTM1*1/*0 39/61 NA 72/28d
GSTT1 n = 122 n = 23
GSTT1*1/*0 83/17 NA 65/35d
MTR n = 147 n = 23
AA/AG/GG (A/G) 71/28/1 (85/15) NA 61/30/9 (76/24)d
MTHFR n = 145 n = 23
CC/CT/TT (C/T) 43/43/14 (64/36) NA 48/43/9 (70/30)d
NA, not available.
aWild-type allele denoted ﬁrst. bThe number of individuals with genotype information varies due to insufﬁcient amounts of DNA
(mainly for AS3MT 12390 and GSTT1). cData from Meza et al. (2005). dData from NCI (2006). 
Table 2. Median metabolite and U-As values. 
No. of cases with 
Group  metabolite data %iAs (range) %MMA (range) %DMA (range) U-As [µg/L (range)]
Pregnant womena 37 of 37 14 (4.5–27) 3.1 (0.1–9.0) 83 (69–92) 233 (111–401)
2004–2005 womenb 110 of 111 12 (1–48) 7.4 (1.2–18) 80 (47–93) 272 (94–724)
aData from Concha et al. (1998b); pregnant women from 2004 and 2005 were included. bPregnant women were excluded. (Applied Biosystems) at the Swegene Resource
Center for Profiling Polygenic Diseases
(Malmö University Hospital). Obtained
sequence chromatograms were analyzed 
with ChromasPro (Technelysium Pty Ltd.,
Tewantin, Australia) and compared with pre-
viously described polymorphic sites using the
SNP Database (NCBI 2006b). For samples
with variations from the consensus sequence,
we performed a new PCR of genomic DNA
followed by a sequencing reaction from the
opposite strand. 
Genotyping of all samples. We per-
formed sequencing for SNPs 12390 and
14215 in AS3MT. The sequencing fragment
for 14215 also included Met287Thr, which
had an allele frequency < 20% in the initial
screening. We analyzed G35991A by allelic
discrimination using the Taqman assay
(Applied Biosystems). The deletion alleles for
GSTM1 (UniGene, Hs.301961) and GSTT1
(UniGene, Hs.568022), as well as GSTM1*0
and GSTT1*0 (homozygotes for the deletion),
were analyzed by multiplex PCR reaction
(Hou et al. 1995; Pemble et al. 1994).
Restriction fragment length polymorphism
(RFLP) analysis was performed for Asp919Gly
in MTR (UniGene, Hs.498187) (Leclerc et al.
1996) and Ala222Val in MTHFR (UniGene,
Hs.214142) (Frosst et al. 1995). Furthermore,
samples taken year 2004 were genotyped for
Glu155del (deletion of glutamate 155) and
Thr217Asn in GSTO1 with RFLP. Linkage
disequilibrium (LD) calculations were per-
formed using Haploview 3.32 (Barrett et al.
2005).
Statistical analyses. We tested deviation
from Hardy-Weinberg equilibrium using chi-
square analysis. Associations between geno-
types (independent variables) and urinary As
metabolites (dependent variables) were ana-
lyzed with one-way analysis of variance
(ANOVA). For subsequent post hoc tests,
adjustments for multiple testing between sub-
groups (i.e. genotypes) were made with
Bonferroni correction. The values for metabo-
lites used in the statistical analyses were %iAs,
%MMA, %DMA, MMA/iAs ratio (first
methylation step), DMA/MMA ratio (second
methylation step), and U-As [all natural log
(ln) transformed]. GSTT1 and GSTM1 geno-
types were divided into two groups: homozy-
gotes for the deletion, GSTM1*0/GSTT1*0; or
those carrying at least one allele, GSTM1*1/
GSTT1*1. Furthermore, multivariate regres-
sion analyses were performed with the same
dependent variables as in the ANOVA analysis
except for U-As, which in this case was used as
an independent variable (exposure marker).
For each dependent variable, we tested each
potentially influential independent variable
[U-As, weight, BMI, age, coca usage (yes/no),
and GW (pregnant women only)]; an indepen-
dent variable was included that provided a
p-value < 0.2. The final models were per-
formed with an interaction term between the
main independent variable and genotype. Data
from individuals with no variant alleles (0)
were used as references values and data from
individuals with one or two variant alleles were
compared with these values. For GSTM1 and
GSTT1, we used individuals with GSTM1*1/
GSTT1*1 as referents. All statistical analyses
were performed using SPSS (version 13; SPSS,
Chicago, IL, USA).
Results
Genotypic background. For AS3MT, all exons
except exon 2 were successfully sequenced. We
found nine previously reported polymorphisms
(NCBI SNP Database 2006b) in the initial
screening. Out of these, three had a frequency
> 20% (Table 1): G12390C (a G-to-C
substitution at nucleotide position 12390,
intron 5), C14215T (intron 7), and G35991A
(intron 9). These variant alleles were in signiﬁ-
cant LD (r2 = 0.95 for positions 12390 and
14215; 0.74 for positions 12390 and 35991;
and 0.78 for positions 14215 and 35991). Of
the remaining six polymorphisms, one was an
exonic polymorphism (Met287Thr), and ﬁve
were intronic [C5019T, a 36-bp deletion at
5051, T5194G, a deletion of TTT at 8788,
and T12590C]. 
For GSTO1, we found no polymorphisms
with an allele frequency > 20%. However, we
did identify a novel genetic variant, T2562C
(one heterozygous carrier), and we verified
five previously reported polymorphisms—
three exonic (Ala140Asp, Glu155del, and
Glu208Lys), and two intronic (A2207G and
a GGC deletion at 2609). These GSTO1
polymorphisms were present in one to three
individuals, mostly in heterozygous form,
with allele frequencies between 1.2–6.0%.
The frequencies of polymorphisms in other
genes studied are shown in Table 1 together
with average allelic frequencies among other
populations studied with similar ancestry (i.e.,
indigenous or European ancestry). 
Metabolite pattern and genotype. The uri-
nary metabolite patterns for the group of
2004–2005 women and for pregnant women
are shown in Table 2. We did not ﬁnd triva-
lent MMAIII in any of the urine samples, and
we did not look for dimethylarsinous acid
(DMAIII), because any small amounts present
would have been oxidized before freezing. 
When performing ANOVA, we found a
statistically signiﬁcant association between the
genotypes AS3MT G12390C, C14215T, and
A35991G and the As metabolite pattern for the
2004–2005 group (A35991G is shown in
Figure 1). The variant alleles were associated
with a decrease in %MMA and an increase in
%DMA in urine, and consequently a higher
ratio for the second methylation step. This was
valid for each of these SNPs separately (Table 3,
data shown only for SNP35991 because the
results for all three SNPs were very similar, with
p-values < 0.001 for %MMA, %DMA, and
DMA/MMA ratio for all SNPs). We found a
difference between all genotypes: the variant
homozygotes displayed the lowest %MMA and
the highest %DMA. The effect was strongest
for %MMA, where the difference was statisti-
cally significant between all genotypes for
SNP12390, SNP14215, and SNP35991,
except for the comparison between heterozy-
gotes and variant homozygotes for SNP35991
(p = 0.10). The %MMA for SNP35991 is
shown in Table 1, and this SNP is presented in
Table 3 (ANOVA). The %iAs showed the
same pattern as %MMA, but this result was not
statistically significant, and neither was the
MMA/iAs ratio (ﬁrst methylation step). 
Genetic polymorphisms influencing As metabolism
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Table 3. Geometric mean As metabolite values (%), ratios of MMA/iAs and DMA/MMA and U-As for different
genotypes for 2004–2005 women. 
Polymorphisma %iAs %MMA %DMA MMA/iAs DMA/MMA U-As No.
AS3MT SNP35991b 
GG 16.7 13.6 68.3 0.82 5.0 285 5
GA 11.8 7.8* 77.3* 0.66 9.9** 280 43
AA 11.0 6.6# 80.4# 0.60 12.2# 261 61
p-Value 0.22 < 0.001 < 0.001 0.5 < 0.001 0.6
MTR
AA 11.2 7.3 79.0 0.65 10.8 270 79
AG 12.0 7.0 79.0 0.58 11.4 272 29
GG 21.7 14.9* 62.2** 0.69 4.2 228 2
p-Value 0.20 0.047 0.006 0.7 0.016 0.8
aOnly SNPs with p-values < 0.1 are presented. bAll AS3MT SNPs gave very similar results; therefore, only SNP35991 is
presented. *p < 0.05, **p < 0.01, and #p < 0.001 compared with wild type. 
Figure 1. %MMA for AS3MT G35991A genotypes.
Error bars indicate 95% conﬁdence intervals. 
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AThe pattern was also valid for all AS3MT
SNPs for pregnant women, where the differ-
ence in %DMA between SNP35991 wild types
and variant homozygotes was statistically signif-
icant (Table 4), whereas the remaining analyses
did not reach statistical signiﬁcance (data not
shown). We found no difference in U-As con-
centration between the different genotypes. We
analyzed arsenic metabolite pattern and variant
allele frequencies in a subset of individuals with
a documented indigenous origin (based on
interviews) in the 2004–2005 group (n = 76).
In this group, the allelic frequency for the vari-
ant allele of 35991 was 77.7%. The differences
in %MMA between the genotypes were even
higher (e.g., for 35991, where the mean
%MMA for GG was 15.5% and for AA 5.7%
compared to 13.6% and 6.3%, respectively, for
the entire 2004–2005 group). For the other
genes studied, no such differences were seen.
Among the individuals with less documented
indigenous origin (n = 34) the variant allelic fre-
quency was 72% and the %MMA was 11.5%
for GG and 8.7% for AA. 
Among the 2004–2005 women, variant
homozygotes of MTR had lower %DMA and
higher %MMA, and thus lower DMA/MMA
ratios (Table 3). However, there were only
two variant homozygotes. Pregnant women
carrying one variant allele of MTR had lower
%DMA (Table 4) and higher %iAs, although
the differences were not statistically signifi-
cant. The pregnant women also displayed
lower %DMA (p = 0.051) for GSTT1*0. 
In the multivariate regression models, the
inﬂuential independent variables were age and
U-As for 2004–2005 women (with an inter-
action term between U-As and genotype) and
GW and U-As for pregnant women (inter-
action term between GW and genotype). The
results from the multivariate regression analy-
sis are presented in Table 5; only models
yielding p-values < 0.1 for the interaction
term are shown. No significant interaction
was found between AS3MT and U-As, but
there was still a strong effect of genotype only,
with a magnitude similar to the ANOVA tests
(data not shown). For the pregnant women,
the effects of U-As or GW on As metabolite
distribution differed depending on certain
genotypes. Carriage of the variant allele of
MTHFR affected the percentage of all
metabolites, as well as the DMA/MMA ratio
(%DMA is shown in Figure 2). For MTR,
there were indications of interactions with
U-As among 2004–2005 women (Figure 3)
and GW among pregnant women: the hetero-
zygotes were associated with larger β coeffi-
cients for %MMA. We observed significant
interaction between GSTM1 and U-As for
%MMA (Figure 4) and DMA/MMA, whereas
interaction between GSTT1 and U-As was
observed for %MMA, %DMA (Figure 5), and
DMA/MMA.
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Table 5. Multivariate regression modeling of effect modiﬁcation by some genotypes on the distribution of
As metabolites (log-transformed). 
β SE p-Value β SE p-Value
For 2004–2005 women, the model contains effect modification by genotype, U-As, and age on the distribution of As
metabolites, with an interaction term of U-As*Genotype. For pregnant women, the model contains effect modiﬁcation by
genotype, U-As, and GW on the distribution of As metabolites, with an interaction term of GW*Genotype. AS3MT poly-
morphisms are not included because no interaction effect was found. 
aGW data are missing for four individuals. bProportion of the total variance of the metabolite levels (ln transformed); values
are unadjusted. cIndividuals with no variant alleles were used as referents and were compared with those with 1 and 2 vari-
ant alleles, respectively. In the pregnant women, no individuals with two variant MTR alleles were found.
dGSTM1*1/GSTT1*1 were used as referents compared with GSTM1*0/GSTT1*0. eU-As data are missing for four 2004–2005
women. *p < 0.05, **p < 0.01, and #p < 0.001 compared with wild type. 
MTHFR
Pregnant women (n = 33)a
iAs (R2)b 0.33
Intercept 1.1 0.95 0.27
Genotype 0/1c  0.97 0.48 0.052
Genotype0/2c  1.2 0.54 0.040*
U-As 0.24 0.17 0.17
GW 0.008 0.014 0.6
Genotype*GW 0/1c  –0.032 0.018 0.094
Genotype*GW 0/2c  –0.036 0.020 0.081
MMA (R2) 0.21
Intercept 0.20 2.4 0.9
Genotype 0/1c  2.5 1.2 0.050*
Genotype 0/2c  2.1 1.4 0.14
U-As –0.059 0.44 0.9
GW 0.039 0.036 0.3
Genotype*GW 0/1c  –0.102 0.047 0.042*
Genotype*GW 0/2c  –0.085 0.051 0.11
DMA (R2) 0.46
Intercept 4.7 0.17 < 0.001
Genotype 0/1c  –0.30 0.087 0.002**
Genotype 0/2c  –0.31 0.099 0.004**
U-As –0.026 0.031 0.4
GW –0.004 0.003 0.17
Genotype *GW 0/1c  0.010 0.003 0.006**
Genotype*GW 0/2c  0.010 0.004 0.010**
DMA/MMA (R2) 0.24
Intercept 4.5 2.5 0.086
Genotype0/1c  –2.8 1.2 0.033*
Genotype0/2c  –2.4 1.4 0.099
U-As 0.033 0.45 0.9
GW –0.042 0.036 0.25
Genotype*GW 0/1c  0.112 0.049 0.029*
Genotype*GW 0/2c  0.095 0.052 0.078
GSTM1
2004–2005 women (n = 100)
MMA (R2) 0.18
Intercept 2.8 0.95 0.004
Genotyped  –4.4 1.3 0.001#
U-As –0.12 0.17 0.5
Genotype*U-Asd  0.79 0.23 0.001#
Age –0.005 0.003 0.1
DMA/MMA (R2) 0.17
Intercept 1.3 1.1 0.2
Genotyped  4.6 1.5 0.001#
U-As 0.15 0.19 0.4
Genotype*U-Asd  –0.85 0.26 0.002#
Age 0.006 0.003 0.067
GSTT1
2004–2005 women (n = 84)
MMA (R2) 0.12
Intercept –0.31 0.83 0.7
Genotyped  3.8 1.8 0.038*
U-As 0.41 0.15 0.006
Genotype*U-Asd  –0.65 0.32 0.047*
Age –0.002 0.003 0.5
DMA (R2) 0.11
Intercept 4.4 0.16 < 0.001
Genotyped  –0.89 0.34 0.011*
U-As –0.017 0.028 0.5
Genotype*U-Asd  0.16 0.06 0.011*
Age 0.001 0.001 0.073
DMA/MMA (R2) 0.12
Intercept 4.7 0.92 < 0.001
Genotyped  –4.7 2.0 0.021*
U-As –0.42 0.16 0.010
Genotype*U-Asd  0.81 0.36 0.026*
Age 0.003 0.004 0.4
MTR
2004–2005 women (n = 106)e
MMA (R2) 0.17
Intercept 1.36 0.75 0.074
Genotype 0/1c  –2.82 1.5 0.058
Genotype 0/2c  1.5 3.0 0.6
U-As 0.14 0.133 0.3
Genotype*U-As 0/1c  0.49 0.26 0.066
Genotype*U-As 0/2c  –0.15 0.54 0.8
Age –0.004 0.003 0.16
Pregnant women (n = 33)
MMA (R2) 0.19
Intercept 1.4 2.6 0.6
Genotypec  –2.1 1.3 0.11
U-As 0.096 0.46 0.8
GW –0.048 0.022 0.034
Genotype*GWc  0.094 0.048 0.059
Table 4. Geometric mean As metabolite values (%), ratios of MMA/iAs and DMA/MMA and U-As for differ-
ent genotypes for pregnant women. 
Polymorphisma %iAs %MMA %DMA MMA/iAs DMA/MMA U-As No.
AS3MT SNP35991b
GG 20.9 4.3 73.7 0.21 16.9 185 4
GA 13.7 2.9 80.6 0.21 27.0 215 9
AA 13.5 2.1 82.2* 0.16 46.9 245 24
p-Value 0.15 0.30 0.033 0.7 0.2 0.3
GSTT1
GSTT1*1 13.3 2.2 81.5 0.18 37.0 230 29
GSTT1*0 18.2 3.5 76.7 0.22 21.6 219 7
p-Value 0.092 0.23 0.051 0.8 0.18 0.8
MTR
AA 13.1 2.3 82.2 0.18 35.9 270 26
AG 16.9 3.0 78.2 0.18 26.3 270 11
p-Value 0.084 0.43 0.079 1.0 0.4 1.0
aOnly SNPs with p-values < 0.1 are presented. bAll AS3MT SNPs gave similar results; therefore, only SNP35991 is pre-
sented. *p < 0.05 compared with wild type. We observed no effect on the MMA/iAs
ratio for any genotype studied (data not
shown).
Discussion 
This study clearly shows that a signiﬁcant part
of the variation in urinary As metabolite dis-
tribution in the Andean people is due to
hereditary differences in As metabolism–
related genes. We found three strongly linked
intronic SNPs in AS3MT that significantly
affected the As metabolite pattern. Carriers of
the variant alleles, especially homozygotes,
had lower %MMA and higher %DMA, and
consequently, a higher DMA/MMA ratio.
For example, variant homozygotes of the
SNP35991 had about half the %MMA com-
pared with wild-type homozygotes. Among
individuals with more documented indigenous
origin, the variant homozygotes had only
about one-third of the %MMA compared with
wild-type homozygotes. The %iAs was also
lower in carriers of variant alleles, although not
signiﬁcantly. This indicates that the effects of
the SNPs are strongly associated with the sec-
ond methylation step in particular. The first
methylation step, which is less sensitive than
the second methylation step to factors such as
sex, excess exposure to As, alcohol, and smok-
ing, may be catalyzed by several different
methyltransferases. It may even occur without
an enzyme (Zakharyan and Aposhian 1999).
Haplotype analysis revealed that the lowest
mean %MMA and highest mean %DMA was
found among individuals showing homo-
zygosity for the variant allele of all three SNPs.
However, there appeared to be no interaction
effect between U-As and AS3MT genotype. 
The three AS3MT polymorphisms were
also found frequently in another study (Meza
et al. 2005) involving Mexican subjects with
European and indigenous ancestry (Table 1).
That study established a significant associa-
tion between the possession of at least one
variant allele for 12390 and DMA/MMA
ratios, but only among children. The authors
suggested that the variant has a developmen-
tally regulated effect on As metabolism.
However, there was a difference in ethnicity
between the groups: The children in the
study were of indigenous ancestry to a greater
extent, and the adults were more of European
ancestry (Meza et al. 2005). In the present
study, we genotyped individuals from villages
where the people had a more documented
Hispanic ancestry. The genotype distribution
of the AS3MT SNPs in these villiages was sig-
niﬁcantly different (data not shown), and was
similar to the distribution found in those with
European ancestry. Our ﬁndings from indige-
nous Andean women strongly indicate that
these variants represent a haplotype for
indigenous ancestry associated with a speciﬁc
As-metabolism proﬁle, irrespective of age. 
Wood et al. (2006) and Drobna et al.
(2004) estimated the functional impact on
AS3MT enzyme activity of genetic variants
occurring in exons. For intronic polymor-
phisms, the function on AS3MT activity is still
completely unknown, and there are no indica-
tions that they are linked to exonic variants
within AS3MT in the SAC population. Only
two individuals from SAC, both pregnant
women, were heterozygous carriers of the high-
activity variant Met287Thr reported by Wood
et al. (2006). These women had rather diver-
gent percentages of MMA: 1.4% and 9.0%. 
Pregnancy affects the metabolite pattern
by increasing the %DMA in urine with
increasing gestational age, probably in concert
with the induction of other methylation reac-
tions required for tissue growth and develop-
ment (Concha et al. 1998b). Therefore, the
pregnant women were analyzed separately in
our study. We observed fairly similar associa-
tions between AS3MT genotype and metabo-
lite distribution in this group, but the results
were not as strong as for the 2004–2005
group. This may be due to the smaller number
of pregnant subjects. However, increased gene
Genetic polymorphisms influencing As metabolism
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Figure 3. %MMA (ln transformed) as a function of U-
As (µg/L) among 2004–2005 women with different
MTR Ala919Gly genotypes. Simple regression lines
within each genotype group are presented (the
regression lines were not derived from the multivari-
ate regression model presented in Table 5; rather,
they illustrate the general direction of interaction). 
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Figure 2. %DMA (ln transformed) as a function of
GW among pregnant women with different MTHFR
Ala222Val genotypes. Simple regression lines within
each genotype group are presented (the regression
lines were not derived from the multivariate regres-
sion model presented in Table 5; rather, they illus-
trate the general direction of interaction). 
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Figure 5. %DMA (ln transformed) as a function of
U-As (µg/L) among 2004–2005 women with different
GSTT1 genotypes. Simple regression lines within
each genotype group are presented (the regres-
sion lines were not derived from the multivariate
regression model presented in Table 5; rather, they
illustrate the general direction of interaction). 
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Figure 4. %MMA (ln transformed) as a function of
U-As (µg/L) among 2004–2005 women with different
GSTM1 genotypes. Simple regression lines within
each genotype group are presented (the regres-
sion lines were not derived from the multivariate
regression model presented in Table 5; rather, they
illustrate the general direction of interaction). 
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methyltransferases, during pregnancy are likely
to blur the association between the genetic
variants of the gene and metabolite pattern. 
We also saw effects on As-metabolism for
other genotypes. However, these results
should be considered as preliminary because
they were not as strong as the results for
AS3MT. In this “explorative” study, multiple
testing was performed. Multiple polymor-
phisms and metabolites were considered, and
several multivariate regression models were
tested. We are aware of the problems with
false-positive ﬁndings, which are inﬂuenced by
the significance level, statistical power, and
prior credibility of the association tested
(Wacholder et al. 2004). We did not formally
adjust the significance level. Sometimes, the
statistical power was low because of the small
numbers of individuals (e.g., among pregnant
women). Problems with false negatives may
also be of concern.
Studies on mice and rabbits have shown
that chemical inhibition of SAM-dependent
methylation reactions result in a marked
decrease in the methylation of As to DMA
(most mammals do not excrete MMA in the
urine), as well as increased tissue concentra-
tions (Marafante and Vahter 1984; Marafante
et al. 1985). Our multivariate regression
analysis indicated that polymorphisms of the
MTHFR and MTR genes, which are involved
in the remethylation of homocysteine to
methionine, affected the metabolite pattern
among pregnant women. The MTHFR
222Val allele has been associated with reduced
enzyme activity and higher plasma homocys-
teine levels (Frosst et al. 1995). As expected, in
the multivariate analysis, individuals with one
or two variant alleles of MTHFR had lower
%DMA and higher %iAs and %MMA, com-
pared with the wild type. On the other hand,
the interaction terms showed an increase in
%DMA (Figure 2) and a decrease in %iAs
and %MMA with increasing gestational age,
compared with the wild type. There are alter-
native pathways for the remethylation of
homocysteine, mainly via choline/betaine,
which may compensate fairly well for loss of
the folate/vitamin B12 pathway (Stead et al.
2006) when the body is not under particular
stress. Possibly, up-regulation of substituting
pathways during pregnancy may balance out
lower activity of MTHFR among carriers of
the variant allele. For MTR, we observed an
effect of both the genotype and the interaction
term on %MMA for heterozygotes, but in
opposite directions. No variant homozygotes
were detected among the pregnant women.
The variant allele of MTR has been found to
be a risk factor for cardiovascular disease and
for cancer (Klerk et al. 2003; Lin et al. 2004;
Zhang et al. 2005). We observed similar but
nonsignificant effects of MTHFR and MTR
(Figure 3) polymorphisms on metabolite
pattern in the 2004–2005 group. However,
these ﬁndings for the folate-related genotypes
need to be conﬁrmed in a larger study. 
Also GSTM1 (%MMA and DMA/MMA)
and GSTT1 (%MMA, %DMA, and DMA/
MMA) modified the metabolite pattern.
Marcos et al. (2006) found that GSTM1*0
individuals excreted more MMA, but we did
not see this effect in the present study using
ANOVA; however, GSTM1*0 carriers had
higher fractions of MMA with increasing
U-As. Chiou et al. (1997) reported an associa-
tion between high %iAs and GSTM1*0. We
found no clear effects on %iAs for this geno-
type in 2004–2005 women (p = 0.7) or in
pregnant women (p = 0.4). Unlike Chiou
et al. (1997), we found no association between
high %DMA and GSTT1*0.
For GSTO1, the frequencies of polymor-
phisms were far too low to affect the distribu-
tion of urinary As metabolites among the
population. The effect of the novel GSTO1
2562 T/C substitution is still to be elucidated.
Marnell et al. (2003) showed that two Mexican
individuals, both heterozygous for Glu155del
and Glu208Lys, displayed signiﬁcantly higher
%iAs in the urine (67–79%). The two individ-
uals in the present study that were hetero-
zygous for Glu155del were also heterozygous
for Glu208Lys, but Marnells’ findings of a
high %iAs in the urine for this genotype was
not veriﬁed. Many other factors, such as expo-
sure level, age, and diseases, may inﬂuence the
metabolism of As (Vahter 2002). 
The population from SAC has been
exposed to As for thousands of years (Figueroa
et al. 1992; Núñez et al. 1991), and we specu-
late that this has resulted in a positive selection
for genotypes that metabolize As in a less toxic
way. The frequencies of the polymorphisms in
AS3MT, associated with increased formation
and excretion of DMA in urine, were very high
compared with other populations (Meza et al.
2005; Wood et al. 2006). Little is known
about the prevalence of As-associated health
effects in this population. We did not ﬁnd a
single case of As-induced hyperkeratosis on the
palms of the hands among the studied women,
although in a previous study (Dulout et al.
1996) we observed an increased frequency of
micronuclei and of trisomy in lymphocytes
from exposed children and women compared
with nonexposed controls. The Andean
women also seem to have lower blood/urine
ratios than other populations (Concha 2001).
Also, As-induced skin lesions have been
observed in Atacameño people in northern
Chile, although mainly in men (Smith et al.
2000), who are known to be more sensitive to
As-induced skin lesions than women (Rahman
et al. 2006). Obviously, a more comprehensive
investigation is needed on the health conse-
quences of As exposure in SAC. 
Identifying polymorphisms, gene–
environment interactions, and related effects
on As metabolism will provide important
information about the mechanisms behind the
biotransformation of As and also facilitate
understanding individual differences in As
metabolism. This will help us to identify sus-
ceptible groups and may provide better risk
estimates for As. Furthermore, this research
has clinical implications in that it may be used
for evaluation of the risks associated with the
current use of arsenicals as a contemporary
pharmaceutical agent. 
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